May 11, 2021 / Care

FDA Approval of Pfizer-BioNTech’s COVID-19 Vaccine for 12-15 Year Olds

Yesterday, May 10, the FDA approved the Pfizer-BioNTech COVID-19 vaccine for use in children ages 12-15 years under emergency use authorization, the same approval seen with Pfizer’s, Moderna’s, and Johnson & Johnson’s adult vaccine approvals.

This is an exciting development, as it expands access to COVID-19 vaccination for adolescents throughout the US, including those with Duchenne. The Pfizer vaccine for adolescents is the same mRNA-based COVID-19 vaccine that was approved for teens and adults ages 16+ at the end of 2020.

This vaccine still requires two shots; after the first shot, adolescents must return three weeks later for a second shot. Pfizer data from clinical trials show that the vaccine was found to be 100% effective in the 12-15-year-old age group.

What does this mean for people living with Duchenne?

If you have questions about the COVID-19 vaccine options and Duchenne, you can learn more here. You can also talk to your Duchenne care team about questions specific to your situation.

While there have not been clinical trials of COVID-19 vaccination specifically in people with Duchenne, data suggests that it could be a lifesaving intervention and the benefits of vaccination outweigh risks associated with Duchenne if someone living with Duchenne were to get COVID-19.

PPMD supports all people with Duchenne having access to COVID-19 vaccination, and all data available so far supports its strong safety profile. We are thrilled to see continued access to our community!

Additional Information

Join Our Mailing List